Abivertinib is a novel oral small molecule tyrosine kinase inhibitor that selectively targets both mutant forms of the epidermal growth…
Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation…
- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1…
NEWTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,…
Odyssey Group International Announces Formation of Military Advisory Board James “Jim” Linder: Major General USA (r) Former Chief of Staff…
Shockwave M5+ IVL Catheter Broadens Options for Treatment of Peripheral ArteriesSANTA CLARA, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Shockwave…
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern…
NEW YORK and SYDNEY, Australia, March 31, 2022 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the…
Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ETHIGHLANDS RANCH, Colo., March 31, 2022 (GLOBE NEWSWIRE) --…
ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved, expected to receive 12 years of marketing exclusivityISELIN, N.J., March 31, 2022 (GLOBE NEWSWIRE)…